{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:32:48Z","timestamp":1793212368952,"version":"4.5.0"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary analysis of the phase III AGEHA study suggested a favorable benefit\u2013risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy (IST; Cohort 1) were included.<\/jats:p>\n                  <jats:p>To present final analysis results of AGEHA, including data on IST-ineligible patients (Cohort 2) and on long-term prophylaxis with emicizumab.<\/jats:p>\n                  <jats:p>For patients in both Cohorts 1 and 2, emicizumab was administered subcutaneously at 6\u2009mg\/kg on Day 1, 3\u2009mg\/kg on Day 2, and 1.5\u2009mg\/kg once weekly from Day 8 onward.<\/jats:p>\n                  <jats:p>Twelve patients (Cohort 1) and two patients (Cohort 2) were enrolled. Duration of emicizumab treatment was 8 to 639 days (median: 44.5 days) in Cohort 1 and 64 and 450 days in Cohort 2. In both cohorts, no major bleeds were observed after initial emicizumab administration. Six patients started their first rehabilitation sessions during emicizumab treatment and no rehabilitation-related bleeds occurred. Twenty-three surgeries were performed under emicizumab prophylaxis and there were no bleeds related to surgeries. Although asymptomatic deep vein thrombosis was reported in one patient in the primary analysis, no other thrombotic events occurred thereafter. Two patients developed anti-emicizumab antibodies, one of whom showed accelerated emicizumab clearance. Tailored IST approaches (delayed initiation, no use, or reduced dose) were successfully executed in three patients undergoing emicizumab prophylaxis.<\/jats:p>\n                  <jats:p>These results suggest that emicizumab prophylaxis has a favorable benefit\u2013risk profile in PwAHA regardless of eligibility for IST.<\/jats:p>","DOI":"10.1055\/a-2384-3585","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T19:31:55Z","timestamp":1723491115000},"page":"449-459","source":"Crossref","is-referenced-by-count":27,"title":["Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy"],"prefix":"10.1055","volume":"125","clinical-trial-number":[{"clinical-trial-number":"jrct2080225056","registry":"10.18810\/jrct"}],"author":[{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan"},{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Nishikii","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-2064","authenticated-orcid":false,"given":"Ryota","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-4162","authenticated-orcid":false,"given":"Ryoto","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-6522","authenticated-orcid":false,"given":"Koichiro","family":"Yoneyama","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[{"name":"Blood Disorders Center, Aiiku Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Mary's Hospital, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Hospital Organization Sendai Medical Center, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Hattori","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami-uonuma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"P W Collins","year":"2007","journal-title":"Blood"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"A Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"A Tiede","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"P Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Z Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"M U Callaghan","year":"2021","journal-title":"Blood"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"E Krumb","year":"2021","journal-title":"Haemophilia"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"A Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref9","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"A Muto","year":"2014","journal-title":"Blood"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"M Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"A Tiede","year":"2023","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hae.12518","article-title":"Safety and efficacy of turoctocog alfa (NovoEight\u00ae) during surgery in patients with haemophilia A: results from the multinational guardian\u2122 clinical trials","volume":"21","author":"E Santagostino","year":"2015","journal-title":"Haemophilia"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.gie.2009.09.040","article-title":"Management of antithrombotic agents for endoscopic procedures","volume":"70","author":"M A Anderson","year":"2009","journal-title":"Gastrointest Endosc"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12185-020-02823-y","article-title":"Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission","volume":"111","author":"Y Ogawa","year":"2020","journal-title":"Int J Hematol"},{"issue":"06","key":"ref15","first-page":"549","article-title":"Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding","volume":"21","author":"S Pasca","year":"2023","journal-title":"Blood Transfus"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"P V Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/hae.12914","article-title":"A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor VIII inhibitor eradication","volume":"22","author":"M Goto","year":"2016","journal-title":"Haemophilia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"108769","DOI":"10.1016\/j.ijscr.2023.108769","article-title":"Acquired haemophilia A in an elderly patient: a case report of functional recovery through physiotherapy","volume":"110","author":"R Tedeschi","year":"2023","journal-title":"Int J Surg Case Rep"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"C Schmitt","year":"2021","journal-title":"Haemophilia"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"O Pizano-Martinez","year":"2023","journal-title":"J Clin Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2384-3585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T18:31:15Z","timestamp":1745951475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2384-3585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":20,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2384-3585","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,12]]},"published":{"date-parts":[[2024,8,12]]}}}